• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Prurigo Nodularis onset during secukinumab treatment of psoriasis: a case report
Secukinumab has been approved by the U.S. FDA and the European Medicines Agency for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis with the documented adverse effects. Here we rep...
Source: Allergy, Asthma and Clinical Immunology - July 5, 2023 Category: Allergy & Immunology Authors: Qingqing Yang, Jiajie Lyu, Yu Gui, Shuling Yu, Jiajie Chen, Haoxue Zhang and Shengxiu Liu Tags: Case report Source Type: research

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases
The goal of harnessing the immune system to fight cancer is not new; it dates back 125 years to when William Coley advocated that the body's response to infection could have anti-tumoural effects.1 However, decades of efforts using vaccines and immune stimulant therapies to harness the immune system to fight tumours have had limited success and at times have been fraught with serious adverse outcomes. Recently, drugs blocking negative immune checkpoint pathways have shown remarkable clinical activity in various solid tumours.2 Several agents targeting two such negative checkpoints, the programmed death-1 (PD-1) pathwa...
Source: Annals of the Rheumatic Diseases - December 8, 2016 Category: Rheumatology Authors: Calabrese, L., Velcheti, V. Tags: Immunology (including allergy), Inflammation, Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Editorials Source Type: research

Biosimilars in rheumatology: the wind of change
The wind of change is blowing in rheumatology. Rheumatologists may soon be exposed to ‘biosimilars’ of the medicines they routinely use as the European Medicines Agency (EMA) has recently issued its final guideline on biosimilar monoclonal antibodies (mAbs)1—a product class of utmost importance for rheumatologists—and a biosimilar infliximab is currently under evaluation for marketing authorisation in Europe,2 and more will come. Rheumatologists, as it appears, are especially challenged these days as many of their patients are already successfully put on long term treatment with individualised drug ...
Source: Annals of the Rheumatic Diseases - February 5, 2013 Category: Rheumatology Authors: Schneider, C. K. Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Editorials Source Type: research